1-phenyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid ethyl ester | 93019-39-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-phenyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid ethyl ester
• 英文别名: 1-Phenyl-4,5,6,7-tetrahydro-1H-indazol-3-carboxylic acid ethyl ester；3-Ethoxycarbonyl-1-phenyl-4,5,6,7-tetrahydro-1H-indazol；ethyl 1-phenyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate；ethyl 1-phenyl-4,5,6,7-tetrahydroindazole-3-carboxylate
• CAS: 93019-39-7
• 化学式: C₁₆H₁₈N₂O₂
• mdl: MFCD08277204
• 分子量: 270.331
• InChiKey: HSDPYKRWVHJZGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-phenyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid ethyl ester 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 生成 1-phenyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid
  参考文献：
  名称：

  Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation

  摘要：

  Dysregulation of the Wnt/beta-catenin signaling pathway has been widely recognized as a pathogenic mechanism for colorectal cancer (CRC). Although numerous Wnt inhibitors have been developed, they commonly suffer from toxicity and unintended effects. Moreover, concerns have been raised in targeting this pathway because of its critical roles in maintaining stem cells and regenerating tissues and organs. On the basis of the anthelmintic drug pyrvinium and previous lead FX1128, we have developed a compound YW2065 (1c) which demonstrated excellent anti-CRC effects in vitro and in vivo. YW2065 achieves its inhibitory activity for Wnt signaling by stabilizing Axin-1, a scaffolding protein that regulates proteasome degradation of beta-catenin. Simultaneously, YW2065 also led to the activation of the tumor suppressor AMPK, providing an additional anticancer mechanism. In addition, YW2065 showed favorable pharmacokinetic properties without obvious toxicity. The anti-CRC effect of YW2065 was highlighted by its promising efficacy in a mice xenograft model.

  DOI：

  10.1021/acs.jmedchem.9b01252
• 作为产物：
  描述：

  1-吗啉基-1-环己烯 、 ethyl (phenylhydrazono)chloroacetate 在 三乙胺 作用下， 以 氯仿 为溶剂， 反应 12.0h， 生成 1-phenyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation

  摘要：

  Dysregulation of the Wnt/beta-catenin signaling pathway has been widely recognized as a pathogenic mechanism for colorectal cancer (CRC). Although numerous Wnt inhibitors have been developed, they commonly suffer from toxicity and unintended effects. Moreover, concerns have been raised in targeting this pathway because of its critical roles in maintaining stem cells and regenerating tissues and organs. On the basis of the anthelmintic drug pyrvinium and previous lead FX1128, we have developed a compound YW2065 (1c) which demonstrated excellent anti-CRC effects in vitro and in vivo. YW2065 achieves its inhibitory activity for Wnt signaling by stabilizing Axin-1, a scaffolding protein that regulates proteasome degradation of beta-catenin. Simultaneously, YW2065 also led to the activation of the tumor suppressor AMPK, providing an additional anticancer mechanism. In addition, YW2065 showed favorable pharmacokinetic properties without obvious toxicity. The anti-CRC effect of YW2065 was highlighted by its promising efficacy in a mice xenograft model.

  DOI：

  10.1021/acs.jmedchem.9b01252

文献信息

• Cyclopentapyrazole and tetrahydroindazole compounds and their use as
  申请人：The Upjohn Company

  公开号：US04851425A1

  公开（公告）日：1989-07-25

  The present invention provides novel compositions of matter and their therapeutic applications. More particularly, the present invention consists of novel cyclopentapyrazole and tetrahydroindazole compounds of formula XXX and their use as antiallergy agents, antiinflammatory agents or intermediates. ##STR1##

  本发明提供了新的物质组合物及其治疗应用。更具体地说，本发明包括新颖的环戊吡唑和四氢吲唑化合物，其化学式为XXX，以及它们用作抗过敏剂、抗炎剂或中间体的用途。
• Haloacetylated enol ethers.<b>11</b>. Synthesis of 1-methyl- and 1-phenyl pyrazole-3(5)-ethyl esters. A one-pot procedure
  作者：Marcos A. P. Martins、Rogério A. Freitag、Adriano Da Rosa、Alex F. C. Flores、Nilo Zanatta、Helio G. Bonacorso

  DOI：10.1002/jhet.5570360133

  日期：1999.1

  A one-pot synthesis of 1-methyl- and 1-phenylpyrazole-3(5)-ethyl esters 2,3a-e by the cyclocondensation of β-alkoxyvinyl trichloromethyl ketones 1a-e with methyl and phenyl hydrazine hydrochloride under mild conditions, is reported. A study using compounds 1a-e with different substituents proved that these are versatile building blocks for the synthesis of pyrazole derivatives, having a 3(5)-ethoxycarbonyl

  在温和的条件下，通过β-烷氧基乙烯基三氯甲基酮1a-e与甲基和苯基肼盐酸盐的环缩合反应，一锅合成1-甲基-和1-苯基吡唑-3（5）-乙酯2,3a-e报告。一项使用具有不同取代基的化合物1a-e进行的研究证明，这些化合物是吡唑衍生物合成的通用构建基，具有3（5）-乙氧羰基取代基，产率高（60-89％）。观察到肼和β-烷氧基乙烯基三氯甲基酮取代基对反应区域化学对形成1，3-和1，5-异构体的影响。
• SMITH, HERMAN W.
  作者：SMITH, HERMAN W.

  DOI：——

  日期：——
• US4851425A
  申请人：——

  公开号：US4851425A

  公开（公告）日：1989-07-25
• [EN] CYCLOPENTAPYRAZOLE AND TETRAHYDROINDAZOLE COMPOUNDS
  申请人：——

  公开号：WO1986007357A3

  公开（公告）日：1987-04-23